BREAKING NEWS: Big Pharma Got EUA A Couple Of Weeks Ago For C-19 Mutation Found A Couple Of Days Ago???

The modern medicine

It looks like yesterday we reported about the new C-19 variant from South Africa. But, within hours, Big Pharma emerged with the vaccine for the new mutation.

Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender

Reuters shared yesterday:

Novavax Inc (NVAX.O) said on Friday it had started working on a version of its COVID-19 vaccine to target the variant detected in South Africa and would have the shot ready for testing and manufacturing in the next few weeks.

The company’s COVID-19 shot contains an actual version of the virus’ spike protein that cannot cause disease but can trigger the immune system. The vaccine developer said it had started developing a spike protein specifically based on the known genetic sequence of the variant, B.1.1.529.

Novavax’s vaccine received its first emergency use approval earlier this month in Indonesia followed by the Philippines. Other vaccine developers, including Germany’s BioNTech SE and Johnson & Johnson, have said they are testing the effectiveness of their shots against the new variant, which is named Omicron by the World Health Organization

And, last night we reported that companies were ready to test the vaccine within the next two weeks.

The Conservative Treehouse reported:

Wow, 72 hours ago no one even heard the name Omicron variant.  Now, in less than three days, a variant has been identified, global travel has been halted, states of emergency have been declared, and now we see a pharmaceutical company announcing the variant-specific vaccine trial that will begin in the U.S. in a few weeks.  This government relationship with Big Pharma is certainly generating some fast action, eh?

Is this a miracle from modern medicine, or is it something else?

Original Article: https://thetruedefender.com/breaking-news-big-pharma-got-eua-a-couple-of-weeks-ago-for-c-19-mutation-found-a-couple-of-days-ago/

Share This Post

Teilen auf facebook
Teilen auf linkedin
Teilen auf twitter
Teilen auf email
de_DE